Pancreatic cancer genes
The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
1. An isolated subgenomic polynucleotide comprising at least twelve contiguous nucleotides of SEQ ID NO:5, or the full complement of said at least twelve contiguous nucleotides of SEQ ID NO:5.
2. The isolated subgenomic polynucleotide of claim 1 comprising at least eighteen contiguous nucleotides of SEQ ID NO:5.
3. An isolated nucleotide probe comprising at least twenty-five contiguous nucleotides of SEQ ID NO:5, or the full complement of said at least twenty-five contiguous nucleotides of SEQ ID NO:5.
4. The isolated nucleotide probe of claim 3 wherein said probe comprises at least fifty contiguous nucleotides of SEQ ID NO:5.
5. A method of diagnosing cancer in a patient comprising determining the amount of a first set of mRNA molecules in a patient sample and in a normal sample, wherein said mP.NA molecules of said first set are complementary to the minus strand of a double-stranded polynucleotide sequence, wherein said double-stranded polynucleotide sequence is selected from the group of polynucleotides as shown in SEQ ID NOs:1, 3-4, 6-11, and 13-14; determining the amount of a second set of mRNA molecules in the patient sample and in the normal sample, wherein said mRNA molecules of said second set are complementary to the minus strand of a double-stranded sequence, wherein said double-stranded polynucleotide sequence is SEQ ID NO: 5; and comparing the determined amounts; wherein a patient sample which contains more of the second set of mRNA molecules than the normal sample and which contains substantially the same amount of the first set of mRNA molecules, as compared to the normal sample, is identified as cancerous.
6. An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of (a) the polynucleotide sequence of SEQ ID NO: 5; and (b) a polynucleotide sequence fully complementary to (a).
7. An isolated nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide encoded for by SEQ ID NO:5, or the full complement thereof.
8. A method of diagnosing cancer in a patient comprising comparing the amount of mRNA molecules in a patient sample and in a normal sample, wherein said mRNA molecules are complementary to the polynucleotide sequence of SEQ ID NO:5, or a naturally occurring variant of SEQ ID NO:5, wherein said naturally occurring variant hybridizes to SEQ ID NO:5 under conditions including a wash in 2×SCC, 0.1% SDS at 50° C. for 20 minutes, or the complement of SEQ ID NO:5 or said naturally occurring variant of SEQ ID NO:5, wherein a patient sample containing more of said mRNA molecules than the normal sample is identified as cancerous and wherein the expression profile of the mRNA molecules is the same as for SEQ ID NO:5.
9. The method of claim 8 wherein the cancer is pancreatic cancer.